Renalase as a new target for the treatment of cardiovascular disease particularly amongst patient with end-stage renal disease
Summary
The antihypertensive market was valued at $31 billion in 2003. The kidney plays an important role in regulating blood pressure and the renal enzyme renin is a target for what is expected to be the next blockbuster class of anti-hypertensives. The report highlighted here identifies a further renal enzyme, renalase that may be another target for the treatment of hypertension.The antihypertensive market was valued at $31 billion in 2003. Although the development of generic equivalents has reduced the market value of the four major antihypertensive classes, the angiotensin II receptor blocker class has experienced strong growth (see Antihypertensives - Together We Stand, Divided We Fail). The kidney plays an important role in regulating blood pressure and the renal enzyme renin is a target for what is expected to be the next blockbuster class of anti-hypertensives. The report highlighted here identifies a further renal enzyme, renalase that may be another target for the treatment of hypertension. Renalase may be particularly important in the increasingly problematic group of patients with end-stage renal disease...[more]
Source LeadDiscovery
Featured on DailyUpdates-Cardiovascular Diseases
